Securities and Exchange Commission
                          Washington, D.  C.  20549

                                 Form 10-QSB


[X]   Quarterly Report Under Section 13 pr 15(d) of the Securities Exchange
      Act of 1934

                      For Quarter Ended: March 31, 2001

                                      OR

[ ]   Transition Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

                        Commission File No.  000-30991


                   SKINOVATION PHARMACEUTICAL INCORPORATED
                     (Name of registrant in its charter)


NEVADA                                       87-0458170
(State of incorporation)                (I. R. S. Employer Identification No.)


                              525 SOUTH 300 EAST
                          SALT LAKE CITY, UTAH 84111
                                (801) 323-2395
        (Address and telephone number of principal executive offices
                       and principal place of business)


     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes [X]   No [   ]

     As of April 27, 2001 the Registrant had a total of 708,000 shares of
common stock issued and outstanding.


<PAGE> 1

                        PART I: FINANCIAL INFORMATION

ITEM 1: FINANCIAL STATEMENTS





                       Skinovation Pharmaceutical, Inc.
                        (A Development Stage Company)
                             Financial Statements
                                March 31, 2001


<PAGE> 2




                       Skinovation Pharmaceutical, Inc.
                        (A Development Stage Company)
                                Balance Sheets



                                    ASSETS
                                                     March 31,   December 31,
                                                        2001        2000
                                                   ------------- -------------
                                                     (Unaudited)

CURRENT ASSETS                                     $          -  $          -
                                                   ------------- -------------

  TOTAL ASSETS                                     $          -  $          -
                                                   ============= =============


                     LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related Party                   $     28,776  $     28,776
                                                   ------------- -------------

  Total Liabilities                                      28,776        28,776
                                                   ------------- -------------
STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000 shares
  authorized; 708,000 shares issued and
  outstanding, respectively                                 708           708

Additional Paid in Capital                               25,148        25,148

Deficit Accumulated During the Development Stage        (54,632)      (54,632)
                                                   ------------- -------------

  Total Stockholders' Equity                            (28,776)      (28,776)
                                                   ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY       $          -  $          -
                                                   ============= =============

<PAGE> 3


                       Skinovation Pharmaceutical, Inc.
                        (A Development Stage Company)
                           Statement of Operations
                                 (Unaudited)


                                 For the three For the three From
                                 months ended  months ended  Inception on
                                 March 31,     March 31,     January 15, 1988
                                 2001          2000          to March 31, 2001
                                 ------------- ------------- --------------

REVENUES                         $          -  $          -  $      27,937
                                 ------------- ------------- --------------
EXPENSES
  General & Administrative                  -             -        119,644
                                 ------------- ------------- --------------

    TOTAL EXPENSES                          -             -        119,644
                                 ------------- ------------- --------------
NET LOSS BEFORE
  DISCONTINUED OPERATIONS                   -             -        (91,707)
                                 ------------- ------------- --------------

GAIN ON DISPOSAL OF OPERATIONS              -             -         37,075
                                 ------------- ------------- --------------

NET INCOME(LOSS)                 $          -  $          -  $     (54,632)
                                 ============= ============= ==============

NET LOSS PER SHARE               $          -  $          -  $       (0.17)
                                 ============= ============= ==============

WEIGHTED AVERAGE
  SHARES OUTSTANDING                  708,000       653,000        330,704
                                 ============= ============= ==============

<PAGE> 4


                       Skinovation Pharmaceutical, Inc.
                        (A Development Stage Company)
                           Statement of Cash Flows
                                 (Unaudited)

                                                                From
                                                                Inception on
                                     For the three months ended January 15,
                                             March 31,          1988 to
                                         2001         2000      March 31, 2001
                                     ------------ ------------- --------------
Cash Flows from Operating Activities

  Net Loss                           $         -  $          -  $     (54,632)
  Less Non-Cash Items:
  Shares issued for services                   -             -         10,433
  Shares issued for debt payment               -             -          1,424
  Increase(Decrease) in accounts
    payable                                    -             -         28,776
  Loss on disposal of PP&E                     -             -          5,263
                                     ------------ ------------- --------------
  Net Cash Provided(Used) by
    Operating Activities                       -             -         (8,736)
                                     ------------ ------------- --------------
Cash Flows from Investing Activities
  Cash paid for PP&E                           -             -         (5,264)
                                     ------------ ------------- --------------
  Net Cash Provided(Used) by
    Investing Activities                       -             -         (5,264)
                                     ------------ ------------- --------------
Cash Flows from Financing Activities
  Cash paid for offering costs                 -             -         (7,000)
  Shares issued for cash                       -             -         21,000
                                     ------------ ------------- --------------
  Net Cash Provided(Used) by
    Financing Activities                       -             -         14,000
                                     ------------ ------------- --------------

Increase in Cash                               -             -              -
                                     ------------ ------------- --------------
Cash and Cash Equivalents at
 Beginning of Period                           -             -              -
                                     ------------ ------------- --------------
Cash and Cash Equivalents at
 End of Period                       $         -  $          -  $           -
                                     ============ ============= ==============

Supplemental Non-Cash Financing Transactions:

  Stock issued for debt payment      $         -  $          -  $       1,424
  Stock issued for services          $         -  $          -  $      10,433
Cash Paid For:
  Interest                           $         -  $          -  $           -
  Income Taxes                       $         -  $          -  $           -



<PAGE> 5


                       Skinovation Pharmaceutical, Inc.
                        (A Development Stage Company)
                      Notes to the Financial Statements
                                March 31, 2001



GENERAL
--------

Skinovation Pharmaceutical, Inc.(the Company) has elected to omit
substantially all footnotes to the financial statements for the nine months
ended March 31, 2001 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report  filed on Form 10-KSB for the year ended
December 31, 2000.

UNAUDITED INFORMATION
----------------------

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are of a normal recurring nature and are, in the opinion of management,
necessary to properly reflect the results of the interim period presented.
The information presented is not necessarily indicative of the results from
operations expected for the full fiscal year.


<PAGE> 6

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

     In this report references to "Skinovation," "we," "us," and "our" refer
to Skinovation Pharmaceutical Incorporated.

Forward Looking Statements

     This form 10-QSB contains certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.  For this
purpose any statements contained in this Form 10-QSB that are not statements
of historical fact may be deemed to be forward-looking statements.  Without
limiting the foregoing, words such as "may," "will," "expect," "believe,"
"anticipate," "estimate" or "continue" or comparable terminology are intended
to identify forward-looking statements.  These statements by their nature
involve substantial risks and uncertainties, and actual results may differ
materially depending on a variety of factors, many of which are not within
Skinovation's control.  These factors include but are not limited to economic
conditions generally and in the market which Skinovation may participate;
competition within Skinovation's chosen market and failure by Skinovation to
successfully develop business relationships.

Plan of Operations

     We are a development stage company with no assets and we have experienced
losses since our inception.  We are dependent on financing to continue our
operations.  For the fiscal year ended December 31, 2000, and the three months
ended March 31, 2001, we had no cash on hand and total current liabilities of
$28,776.  The $28,766 account payable is related to accounting and legal fees
paid on our behalf in fiscal year 1999.

     We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
may be met by loans from our directors, officers and stockholders.  We may
repay these loans, costs of services  and advancements with cash, if
available, or we may convert them into common stock.  Also, management
anticipates future private placements of our common shares may fund our
operations.

     We will incur expenses due to the legal and accounting services required
to prepare and file reports with the Securities and Exchange Commission.
Also, our management must expend time and effort to assist in the preparation
and review of such reports.  We anticipate that such expenses will be paid for
by loans or equity transactions.  In the event we acquire a business
opportunity we may incur additional expenses related to proxy or information
statements we must provide to our stockholders which disclose that company's
business operations, management and financial condition.  In addition, the
acquired or merged company will be subject to these same reporting
obligations.

     Our management intends to actively pursue business opportunities during
the next twelve months.  All risks inherent in new and inexperienced
enterprises are inherent in our business.  We have not made a formal study of
the economic potential of any business.  At the present, we have not
identified any assets or business opportunities for acquisition.

     Based on current economic and regulatory conditions, management believes
that it is possible, if not probable, for a company like ours, without many
assets or liabilities, to negotiate a merger or

<PAGE> 8

acquisition with a viable private company.  The opportunity arises principally
because of the high legal and accounting fees and the length of time
associated with the registration process of "going public".  However, should
any of these conditions change, it is very possible that there would be little
or no economic value for anyone taking over control of Skinovation.

     Potential investors must recognize that because of our limited capital
available for investigation and management's limited experience in business
analysis we may not discover or adequately evaluate adverse facts about the
business opportunity to be acquired.  Also, we intend to concentrate our
acquisition efforts on properties or businesses that we believe to be
undervalued or that we believe may realize a substantial benefit from being
publicly owned.  Investors should expect that any acquisition candidate may
have little or no operating history, or a history of losses or low
profitability.

     It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

     Should a merger or acquisition prove unsuccessful, it is possible that we
may decide not to pursue further acquisition activities and management may
abandon its activities and our shares would become worthless.


                         PART II - OTHER INFORMATION

Item 6.  Exhibits and Reports on Form 8-K

(a)   Exhibits

Exhibit Number          Description
--------------          ------------

3.1          Articles of Incorporation, dated January 15, 1988 (Incorporated
             by reference to exhibit 3.1 of the Form-SB, filed July 11, 2000)

3.2          Certificate of Amendment, dated August 5, 1992 (Incorporated by
             reference to exhibit 3.2 of the Form-SB, filed July 11, 2000)

3.3          Bylaws of Skinovation Pharmaceutical Incorporated (Incorporated
             by reference to exhibit 3.3 of the Form-SB, filed July 11, 2000)


(b)  Reports on Form 8-K

     None.



<PAGE> 9

                                  SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.

           5-1-01
Date_________________________    Skinovation Pharmaceutical Incorporated



                                       /s/ John W. Peters
                                 By: ____________________________________
                                     John W. Peters, President and Director



                                      10